B. Zinman

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Serum urate and cardiovascular events in the DCCT/EDIC study”.

Serum urate and cardiovascular events in the DCCT/EDIC study

Scientific Reports(2021)10.1038/s41598-021-90785-4

N/A

0.421DataRank · unranked

7 citations

Barbara H. Braffett, Arpita Basu, Ionut Bebu, Samuel Dagogo‐Jack, Trevor J. Orchard +86 more

Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial

UNC Libraries(2020)10.17615/eqw9-qw52

N/A

0DataRank · unranked

6 citations

S.P. Marso, Spencer Rasmussen, S. Verma, S.C. Bain, B. Zinman +9 more

Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)

UNC Libraries(2020)10.17615/tazj-ry27

N/A

0DataRank · unranked

1 citations

S.S. Emerson, R.E. Pratley, B. Zinman, M. Lange, T.R. Pieber +9 more

Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use results from the LEADER trial

UNC Libraries(2020)10.17615/ct1e-g414

N/A

0DataRank · unranked

1 citations

H. Bosch-Traberg, S. Rasmussen, S.C. Bain, S. Verma, J. Buse +7 more

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PioNEER 8 trial

UNC Libraries(2020)10.17615/1bzn-7t47

N/A

0DataRank · unranked

13 citations

S.B. Harris, J.B. Buse, B. Zinman, B. Cariou, M.J. Tarp-Johansen +4 more

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)

UNC Libraries(2020)10.17615/628n-ex62

N/A

0DataRank · unranked

0 citations

N.R. Poulter, R.E. Pratley, Ting‐Ting Jia, R. Pop-Busui, M.B. Hansen +7 more

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

UNC Libraries(2020)10.17615/6txp-rv36

N/A

0DataRank · unranked

0 citations

D.K. McGuire, C.T. Hansen, B. Zinman, S.P. Marso, DEVOTE Study Group +9 more

Liraglutide and Glycaemic Outcomes in the LEADER Trial

UNC Libraries(2020)10.17615/kz1k-4223

N/A

0DataRank · unranked

0 citations

D.D. Ørsted, J.B. Buse, H. Bosch-Traberg, The LEADER Publication Committee on behalf of the LEADER Trial Investigators, H. Frimer-Larsen +2 more

Cardiovascular risk reduction with liraglutide: An exploratory mediation analysis of the leader trial

UNC Libraries(2020)10.17615/1rnr-dq63

N/A

0DataRank · unranked

0 citations

S. Pocock, B. Zinman, S.E. Nissen, M.A. Nauck, J.F.E. Mann +7 more